Physician profile
Cathy Le
NPI 1740022326
$1,526.04
in general payments reported to CMS, 2019-2025
19 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $135 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463 · Education: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.04 |
| Education | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $438.71 | 2024-2025 | Amvuttra |
| Boston Scientific Corporation | $172.35 | 2025 | Versacross Access Solution |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.14 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $105.12 | 2025 | |
| Medtronic, INC. | $99.24 | 2024-2025 | Symplicity G3, In.Pact Av |
| Kestra Medical Technology Services, INC. | $58.15 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $57.82 | 2025 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $54.55 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $47.91 | 2025 | |
| Pfizer INC. | $47.90 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $46.04 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $44.44 | 2025 | Verquvo, Capvaxive |
| Bridgebio Pharma, INC. | $43.08 | 2025 | Attruby |
| Abiomed | $40.97 | 2025 | |
| Medicomp INC | $37.54 | 2025 | Telepatch Cardiac Monitor |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $35.57 | 2024 | Cardiva Vascade 6/7f Vcs |
| Xeris Pharmaceuticals, INC. | $24.14 | 2025 | Recorlev |
| Kiniksa Pharmaceuticals International, Plc | $22.72 | 2024 | Arcalyst |
| Lilly USA, LLC | $18.65 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.